...
首页> 外文期刊>Clinical nephrology >The effect of heparinized catheter lock solutions on systemic anticoagulation in hemodialysis patients.
【24h】

The effect of heparinized catheter lock solutions on systemic anticoagulation in hemodialysis patients.

机译:肝素化的导管锁定溶液对血液透析患者全身抗凝的作用。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Hemodialysis catheter thrombosis is associated with loss of catheter patency, catheter-related bacteremia and sepsis. To limit these risks, many renal units use heparin as a catheter-locking solution. In this study we investigate the effect of different concentrations of heparin catheter lock solution on systemic anticoagulation in an investigator-blinded randomized study of patients with non-tunneled (temporary) central venous catheters. METHODS: 28 consecutive patients requiring insertion of a temporary non-tunneled dual lumen central venous hemodialysis catheter were randomly allocated to receive either heparin 5,000 IU/ml or heparin 1,000 IU/ml as catheter lock solutions. The primary outcome measure was the difference in activated partial thromboplastin time (APTT) at 10 minutes following catheter locking with heparin 5,000 IU/ml and heparin 1,000 IU/ml. Secondary outcomes included intradialytic blood flow rates, catheter removal due to insufficient hemodialysis blood flow to maintain hemodialysis and catheter-related bacteremia. RESULTS: 13 patients were randomized to the heparin 1,000 IU/ml group with 15 patients randomized to the heparin 5,000 IU/ml group. There was a statistically significant increase in APTT at 10 minutes between groups with median +22.2% (range 0 - 210) rise in APTT in the heparin 1,000 IU/ml group compared with +373.7% (range 133 - 800) in the heparin 5,000 IU/ml group (p < 0.001). There was no statistically significant difference between groups with the secondary outcomes of intradialytic blood flow, catheter failure rates and catheter-related bacteremia rates. CONCLUSIONS: Heparin 1,000 IU/ml catheter lock solution confers a significantly lower risk of systemic heparinization than heparin 5,000 IU/ml without any overtly detrimental effect on intradialytic blood flow, catheter failure rates and catheter-related bacteremia rates.
机译:背景:血液透析导管血栓形成与导管通畅性丧失,导管相关菌血症和败血症有关。为了限制这些风险,许多肾脏单位都使用肝素作为导管锁定溶液。在这项研究中,我们在一项针对非隧道(临时)中央静脉导管患者的研究者盲目的随机研究中,研究了不同浓度的肝素导管锁定溶液对全身抗凝的影响。方法:连续28例需要插入临时非隧道双腔中央静脉血液透析导管的患者被随机分配接受5,000 IU / ml肝素或1,000 IU / ml肝素作为导管锁定溶液。主要结果指标是用肝素5,000 IU / ml和肝素1,000 IU / ml锁定导管后10分钟激活的部分凝血活酶时间(APTT)的差异。次要结局包括透析内血流速度,由于血液透析血流不足以维持血液透析而拔除导管以及导管相关菌血症。结果:13例患者被随机分配至肝素1,000 IU / ml组,15例患者被随机分配至肝素5,000 IU / ml组。两组之间APTT在10分钟时有统计上的显着增加,肝素1,000 IU / ml组中APTT升高了中位数+ 22.2%(范围为0-210),而肝素5,000中为+ 373.7%(范围133-800) IU / ml组(p <0.001)。两组之间的透析内血流,导管衰竭率和导管相关菌血症率的次要结局在统计学上无显着差异。结论:肝素1,000 IU / ml的导管锁定溶液比肝素5,000 IU / ml的系统性肝素化风险显着降低,而对透析内血流,导管衰竭率和导管相关菌血症率没有明显的不利影响。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号